High Prevalence of Clinically Silent Severe Mitral Regurgitation in Patients with Heart Failure: Role for Echocardiography

2006 ◽  
Vol 19 (12) ◽  
pp. 1458-1461 ◽  
Author(s):  
Padmini Varadarajan ◽  
Sanjay Sharma ◽  
J. Thomas Heywood ◽  
Ramdas G. Pai
Keyword(s):  
Heart Failure ◽  
Mitral Regurgitation ◽  
Severe Mitral Regurgitation ◽  
Patients With Heart Failure ◽  
High Prevalence

The Novel Use of Mitraclip in a Patient with Combined Multiple Myeloma and Heart Failure with Severe Mitral Regurgitation

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Abu Ghosh Z ◽  
◽  
Beeri R ◽  
Falah B ◽  
Pertz A ◽  
...  
Keyword(s):  
Heart Failure ◽  
Multiple Myeloma ◽  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Mitral Valve Repair ◽  
Severe Mitral Regurgitation ◽  
The Novel ◽  
Valve Repair ◽  
Oncological Treatment ◽  
Patients With Heart Failure

Oncology patients with Heart Failure (HF) and severe Mitral Regurgitation (MR) are often considered to have a prohibitive risk for surgical mitral valve repair/replacement. We describe a patient with active multiple myeloma and significant HF and MR who was treated with MitraClip, which improved symptoms and allowed delivery of optimal oncological treatment.

scholarly journals Value of MitraClip in Reducing Functional Mitral Regurgitation

2019 ◽  
Vol 13 (1) ◽  
pp. 30-34
Author(s):  
Mehmet Ali Elbey ◽  
Luis Augusto Palma Dallan ◽  
Guilherme Ferragut Attizzani ◽  
Keyword(s):  
Heart Failure ◽  
Mitral Regurgitation ◽  
Ventricular Dysfunction ◽  
Left Ventricular ◽  
Functional Mitral Regurgitation ◽  
Current Evidence ◽  
Successful Implementation ◽  
Severe Mitral Regurgitation ◽  
Percutaneous Mitral Valve Repair ◽  
Patients With Heart Failure

Patients with heart failure who have secondary severe mitral regurgitation due to left ventricular dysfunction have a poor prognosis, with high rates of rehospitalization and mortality. Percutaneous mitral valve repair using the MitraClip (Abbott) has been shown to be safe and effective in secondary severe mitral regurgitation with heart failure. The number of MitraClip procedures performed has increased significantly, as recently published large, randomized clinical studies have shown. However, these studies have drawn different conclusions. This review aims to summarize the current evidence for the MitraClip procedure and provide information for its safe and successful implementation, comparing the studies that examined the use of MitraClip versus medical therapy alone or surgical repair for severe secondary mitral regurgitation.

Mid-term results of percutaneous treatment of severe mitral regurgitation with MitraClip in patients with heart failure

2021 ◽  
Vol 20 (2) ◽  
pp. 102-105
Author(s):  
Michaela Červinková ◽  
Jiří Hlaváček ◽  
Petr Vojtíšek ◽  
Martin Kvašňák ◽  
Pavel Červinka
Keyword(s):  
Heart Failure ◽  
Mitral Regurgitation ◽  
Percutaneous Treatment ◽  
Severe Mitral Regurgitation ◽  
Patients With Heart Failure ◽  
Mid Term Results

scholarly journals RESERVOIR FUNCTION OF LEFT ATRIUM IS IMPAIRED IN PATIENTS WITH HEART FAILURE AND SEVERE MITRAL REGURGITATION

2011 ◽  
Vol 57 (14) ◽  
pp. E1403
Author(s):  
Tomohiro Hayashi ◽  
Makoto Amaki ◽  
Akira Funada ◽  
Hiroyuki Takahama ◽  
Takuya Hasegawa ◽  
...  
Keyword(s):  
Heart Failure ◽  
Mitral Regurgitation ◽  
Left Atrium ◽  
Severe Mitral Regurgitation ◽  
Reservoir Function ◽  
Patients With Heart Failure

Transcatheter mitral valve replacement

2018 ◽  
pp. 629-638
Author(s):  
Ricardo Boix Garibo ◽  
Mohsin Uzzaman ◽  
Michael Ghosh-Dastidar ◽  
Vinayak Bapat
Keyword(s):  
Heart Failure ◽  
Mitral Valve ◽  
Mitral Regurgitation ◽  
Mitral Valve Regurgitation ◽  
Common Disease ◽  
Severe Mitral Regurgitation ◽  
Valve Regurgitation ◽  
Number Of Patients ◽  
Transcatheter Mitral Valve Replacement ◽  
Patients With Heart Failure

Mitral valve regurgitation is a common disease affecting a large number of patients with heart failure. It is more prevalent in Europe and North America and predominantly in older ages. It has been estimated that moderate to severe mitral regurgitation will double its prevalence by 2030, affecting more than 4 million people. Mitral regurgitation is the second most common valve disease requiring surgery in Europe.

The Results of the Use of Angiotensin Receptor Inhibitors and Neprilisin in Secondary Functional Mitral Regurgitation in Outpatient Practice

2020 ◽  
Vol 75 (5) ◽  
pp. 514-522
Author(s):  
Alexey S. Ryazanov ◽  
Konstantin I. Kapitonov ◽  
Mariya V. Makarovskaya ◽  
Alexey A. Kudryavtsev
Keyword(s):  
Heart Failure ◽  
Left Ventricle ◽  
Mitral Regurgitation ◽  
Effective Area ◽  
Left Ventricular ◽  
Functional Mitral Regurgitation ◽  
Angiotensin Receptor ◽  
Optimal Drug ◽  
Patients With Heart Failure ◽  
Valsartan Group

Background. Morbidity and mortality in patients with functional mitral regurgitation (FMR) remains high, however, no pharmacological therapy has been proven to be effective.Aimsto study the effect of sacubitrile/valsartan and valsartan on functional mitral regurgitation in chronic heart failure.Methods.This double-blind study randomly assigned sacubitrile/valsartan or valsartan in addition to standard drug therapy for heart failure among 100 patients with heart failure with chronic FMR (secondary to left ventricular (LV) dysfunction). The primary endpoint was a change in the effective area of the regurgitation hole during the 12-month follow-up. Secondary endpoints included changes in the volume of regurgitation, the final systolic volume of the left ventricle, the final diastolic volume of the left ventricle, and the area of incomplete closure of the mitral valves.Results.The decrease in the effective area of the regurgitation hole was significantly more pronounced in the sacubitrile/valsartan group than in the valsartan group (0.070.066against0.030.058sm2; p=0.018)in the treatment efficacy analysis, which included 100patients (100%). The regurgitation volume also significantly decreased in the sacubitrile/valsartan group compared to the valsartan group (mean difference:8.4ml; 95%CI, from 13.2 until 1.9;р=0.21). There were no significant differences between the groups regarding changes in the area ofincomplete closure of the mitral valves and LV volumes, with the exception of the index of the final LV diastolic volume (p=0.07).Conclusion.Among patients with secondary FMR, sacubitril/valsartan reduced MR more than valsartan. Thus, angiotensin receptor inhibitors and neprilysin can be considered for optimal drug treatment of patients with heart failure and FMR.

Redistribution of cardiac output during exercise by functional mitral regurgitation in heart failure: compensatory O2 peripheral uptake to delivery failure

2020 ◽  
Vol 319 (1) ◽  
pp. H100-H108
Author(s):  
Marco Guazzi ◽  
Greta Generati ◽  
Barry Borlaug ◽  
Eleonora Alfonzetti ◽  
Tadafumi Sugimoto ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Output ◽  
Gas Exchange ◽  
Mitral Regurgitation ◽  
Functional Mitral Regurgitation ◽  
Functional Evaluation ◽  
Severe Mitral Regurgitation ◽  
Reduced Ejection Fraction ◽  
Heart Failure Patients ◽  
Fraction Versus

This is an analysis involving 134 heart failure patients with reduced ejection fraction versus 80 controls investigated during functional evaluation with gas exchange and hemodynamic, addressing the severe mitral regurgitation phenotype and testing the hypothesis that the backward cardiac output redistribution to the lung during exercise impairs delivery and overexpresses peripheral extraction. This information is new and has important implications in the management of heart failure.

scholarly journals Expert consensus regarding treatment of iron deficiency in stable and decompensated patients with heart failure

Kardiologiia ◽  
2021 ◽  
Vol 61 (4) ◽  
pp. 73-78
Author(s):  
Yu. V. Mareev ◽  
S. R. Gilarevsky ◽  
Yu. L. Begrambekova ◽  
Yu. M. Lopatin ◽  
A. A. Garganeeva ◽  
...  
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ferric Carboxymaltose ◽  
Ventricular Ejection Fraction ◽  
Patients With Heart Failure ◽  
High Prevalence ◽  
Acute Decompensation

In recent years there has been significant interest in treating iron deficiency (ID) in patients with heart failure (HF) due to its high prevalence and detrimental effects in this population. As stated in the 2020 Russain HF guidelines, Intravenous ferric carboxymaltose remains the only proven therapy for ID.This document was prompted by the results from the recent AFFIRM-AHF trial which demonstrates that treatment of ID after acute HF decompensation reduces the risk of future decompensations. Experts have concluded that in HF patients with acute decompensation, a left ventricular ejection fraction of < 50% and ID, Intravenous ferric carboxymaltose reduces future HF hospitalisations. Patients with stable HF may also benefit from treatment of ID to improve quality of life and alleviate symptoms.  It is, therefore, reasonable to screen for and treat ID in patients with HF.

Sign in / Sign up

Export Citation Format

Share Document